blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2794009

EP2794009 - BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  06.07.2018
Database last updated on 03.09.2024
FormerThe patent has been granted
Status updated on  28.07.2017
FormerGrant of patent is intended
Status updated on  20.03.2017
FormerExamination is in progress
Status updated on  07.02.2017
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
Kancera AB
Karolinska Institutet Science Park
Banvaktsvägen 22
17148 Solna / SE
[2014/44]
Inventor(s)01 / MARTINSSON, Jessica
Turebergs allé 13
S-191 64 Sollentuna / SE
02 / FÄRNEGÅRDH, Katarina
Borstvetevägen 6
S-178 35 Ekerö / SE
03 / JÖNSSON, Mattias
Forngravsvägen 4A
S-741 42 Knivsta / SE
04 / RINGOM, Rune
Murargatan 20a
S-754 37 Uppsala / SE
 [2014/48]
Former [2014/44]01 / MARTINSSON, Jessica
Hästhagsvägen 23C
S-191 63 Sollentuna / SE
02 / FÄRNEGÅRDH, Katarina
Borstvetevägen 6
S-178 35 Ekerö / SE
03 / JÖNSSON, Mattias
Forngravsvägen 4A
S-741 42 Knivsta / SE
04 / RINGOM, Rune
Murargatan 20a
S-754 37 Uppsala / SE
Representative(s)Brann AB
P.O. Box 3690
Sveavägen 63
103 59 Stockholm / SE
[N/P]
Former [2017/35]Brann AB
P.O. Box 3690
Drottninggatan 27
103 59 Stockholm / SE
Former [2014/44]Brann AB
P.O. Box 12246
102 26 Stockholm / SE
Application number, filing date12806515.821.12.2012
[2017/35]
WO2012EP76836
Priority number, dateUS201161579360P22.12.2011         Original published format: US 201161579360 P
EP2011019545622.12.2011         Original published format: EP 11195456
EP2011019596228.12.2011         Original published format: EP 11195962
[2014/44]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013093095
Date:27.06.2013
Language:EN
[2013/26]
Type: A1 Application with search report 
No.:EP2794009
Date:29.10.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 27.06.2013 takes the place of the publication of the European patent application.
[2014/44]
Type: B1 Patent specification 
No.:EP2794009
Date:30.08.2017
Language:EN
[2017/35]
Search report(s)International search report - published on:EP27.06.2013
ClassificationIPC:A61P35/00, A61P29/00, A61K31/381, A61K31/41, A61K31/18, A61K31/343, A61K31/427, A61K31/4436, A61K31/506, C07C311/13, C07C311/21, C07C311/27, C07C311/29, C07C311/39, C07C311/46
[2014/44]
CPC:
C07D409/14 (EP,US); A61P1/00 (EP); A61P29/00 (EP);
A61P35/00 (EP); A61P43/00 (EP); C07C311/21 (US);
C07D213/34 (EP,US); C07D213/71 (EP,US); C07D213/74 (EP,US);
C07D215/12 (EP,US); C07D231/38 (EP,US); C07D261/14 (EP,US);
C07D277/26 (EP,US); C07D285/15 (EP,US); C07D295/088 (EP,US);
C07D295/096 (EP,US); C07D295/192 (EP,US); C07D307/64 (EP,US);
C07D307/79 (EP,US); C07D307/82 (EP,US); C07D333/22 (EP,US);
C07D333/34 (EP,US); C07D333/62 (EP,US); C07D405/04 (EP,US);
C07D409/04 (EP,US); C07D409/12 (EP,US); C07C2601/16 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/44]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:BISARYLSULFONAMIDE FÜR DIE BEHANDLUNG EINER ENTZÜNDUNG UND KREBS[2016/35]
English:BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER[2014/44]
French:BISARYLE-SULFONAMIDES UTILES POUR LE TRAITEMENT DES INFLAMMATIONS ET DU CANCER[2016/35]
Former [2014/44]FÜR DIE BEHANDLUNG VON ENTZÜNDUNGEN UND KREBS NÜTZLICHE BISARYLSULFONAMIDE
Former [2014/44]BISARYLSULFONAMIDES UTILES DANS LE TRAITEMENT D'INFLAMMATIONS ET DE CANCER
Entry into regional phase08.07.2014National basic fee paid 
08.07.2014Designation fee(s) paid 
08.07.2014Examination fee paid 
Examination procedure08.07.2014Examination requested  [2014/44]
23.01.2015Amendment by applicant (claims and/or description)
28.10.2015Despatch of a communication from the examining division (Time limit: M04)
01.02.2016Reply to a communication from the examining division
25.10.2016Communication of intention to grant the patent
06.02.2017Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
21.03.2017Communication of intention to grant the patent
21.07.2017Fee for grant paid
21.07.2017Fee for publishing/printing paid
21.07.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  28.10.2015
Opposition(s)31.05.2018No opposition filed within time limit [2018/32]
Fees paidRenewal fee
30.12.2014Renewal fee patent year 03
14.12.2015Renewal fee patent year 04
15.12.2016Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU21.12.2012
AL30.08.2017
AT30.08.2017
CY30.08.2017
CZ30.08.2017
DK30.08.2017
EE30.08.2017
HR30.08.2017
LT30.08.2017
LV30.08.2017
MK30.08.2017
PL30.08.2017
PT30.08.2017
RO30.08.2017
RS30.08.2017
SI30.08.2017
SK30.08.2017
SM30.08.2017
TR30.08.2017
BG30.11.2017
NO30.11.2017
GR01.12.2017
IS30.12.2017
[2020/34]
Former [2020/28]HU21.12.2012
AT30.08.2017
CY30.08.2017
CZ30.08.2017
DK30.08.2017
EE30.08.2017
HR30.08.2017
LT30.08.2017
LV30.08.2017
MK30.08.2017
PL30.08.2017
PT30.08.2017
RO30.08.2017
RS30.08.2017
SI30.08.2017
SK30.08.2017
SM30.08.2017
TR30.08.2017
BG30.11.2017
NO30.11.2017
GR01.12.2017
IS30.12.2017
Former [2020/16]HU21.12.2012
AT30.08.2017
CY30.08.2017
CZ30.08.2017
DK30.08.2017
EE30.08.2017
HR30.08.2017
LT30.08.2017
LV30.08.2017
MK30.08.2017
PL30.08.2017
RO30.08.2017
RS30.08.2017
SI30.08.2017
SK30.08.2017
SM30.08.2017
TR30.08.2017
BG30.11.2017
NO30.11.2017
GR01.12.2017
IS30.12.2017
Former [2019/51]HU21.12.2012
AT30.08.2017
CY30.08.2017
CZ30.08.2017
DK30.08.2017
EE30.08.2017
HR30.08.2017
LT30.08.2017
LV30.08.2017
MK30.08.2017
PL30.08.2017
RO30.08.2017
RS30.08.2017
SI30.08.2017
SK30.08.2017
SM30.08.2017
BG30.11.2017
NO30.11.2017
GR01.12.2017
IS30.12.2017
Former [2019/47]HU21.12.2012
AT30.08.2017
CY30.08.2017
CZ30.08.2017
DK30.08.2017
EE30.08.2017
HR30.08.2017
LT30.08.2017
LV30.08.2017
PL30.08.2017
RO30.08.2017
RS30.08.2017
SI30.08.2017
SK30.08.2017
SM30.08.2017
BG30.11.2017
NO30.11.2017
GR01.12.2017
IS30.12.2017
Former [2019/31]HU21.12.2012
AT30.08.2017
CZ30.08.2017
DK30.08.2017
EE30.08.2017
HR30.08.2017
LT30.08.2017
LV30.08.2017
PL30.08.2017
RO30.08.2017
RS30.08.2017
SI30.08.2017
SK30.08.2017
SM30.08.2017
BG30.11.2017
NO30.11.2017
GR01.12.2017
IS30.12.2017
Former [2018/39]AT30.08.2017
CZ30.08.2017
DK30.08.2017
EE30.08.2017
HR30.08.2017
LT30.08.2017
LV30.08.2017
PL30.08.2017
RO30.08.2017
RS30.08.2017
SI30.08.2017
SK30.08.2017
SM30.08.2017
BG30.11.2017
NO30.11.2017
GR01.12.2017
IS30.12.2017
Former [2018/24]AT30.08.2017
CZ30.08.2017
DK30.08.2017
EE30.08.2017
HR30.08.2017
LT30.08.2017
LV30.08.2017
PL30.08.2017
RO30.08.2017
RS30.08.2017
SK30.08.2017
SM30.08.2017
BG30.11.2017
NO30.11.2017
GR01.12.2017
IS30.12.2017
Former [2018/23]AT30.08.2017
CZ30.08.2017
DK30.08.2017
EE30.08.2017
HR30.08.2017
LT30.08.2017
LV30.08.2017
PL30.08.2017
RO30.08.2017
RS30.08.2017
SK30.08.2017
BG30.11.2017
NO30.11.2017
GR01.12.2017
IS30.12.2017
Former [2018/21]AT30.08.2017
CZ30.08.2017
DK30.08.2017
HR30.08.2017
LT30.08.2017
LV30.08.2017
RS30.08.2017
BG30.11.2017
NO30.11.2017
GR01.12.2017
IS30.12.2017
Former [2018/12]AT30.08.2017
HR30.08.2017
LT30.08.2017
LV30.08.2017
RS30.08.2017
BG30.11.2017
NO30.11.2017
GR01.12.2017
IS30.12.2017
Former [2018/11]AT30.08.2017
HR30.08.2017
LT30.08.2017
RS30.08.2017
BG30.11.2017
NO30.11.2017
GR01.12.2017
IS30.12.2017
Former [2018/10]AT30.08.2017
HR30.08.2017
LT30.08.2017
RS30.08.2017
NO30.11.2017
Former [2018/07]LT30.08.2017
NO30.11.2017
Cited inInternational search[A]EP0269859  (OTSUKA PHARMA CO LTD [JP]) [A] 1-19 * abstract * * example 112 *;
 [A]US2004167128  (COMESS KENNETH M [US], et al) [A] 1-19 * abstract * * page 22 - page 120; examples 1-618 * * claims 1-21 *;
 [A]WO2005060963  (PFIZER [US], et al) [A] 1-19 * abstract * * page 55 - page 96; table 1 * * claims 1-19 *;
 [A]WO2008156783  (UNIV LOUISVILLE RES FOUND [US], et al) [A] 1-19 * abstract * * claims 1-77 *;
 [A]WO2010076034  (EUROPEAN MOLECULAR BIOLOGY LAB EMBL [DE], et al) [A] 1-19 * abstract * * page 47 - page 49; table 2; compounds 1-29 * * page 51 - page 57; table 3; compounds 30-280 * * claims 1-19 *;
 [A]CN101817767  (SHANGHAI INST BIOL SCIENCES, et al) [A] 1-19 * abstract * * paragraphs [0045] - [0047] * * claims *;
 [A]US2010267815  (TELANG SUCHETA [US], et al) [A] 1-19 * abstract * * claims 1-28 *;
 [A]WO2011103557  (ADVANCED CANCER THERAPEUTICS LLC [US], et al) [A] 1-19 * abstract * * claims 1-12 *;
 [XP]WO2011161201  (KANCERA AB [SE], et al) [XP] 16* the whole document *;
 [A]  - CROCHET R B ET AL H, "Investigating combinatorial approaches in virtual screening on human inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3): A case study for small molecule kinases", ANALYTICAL BIOCHEMISTRY 20111101 ACADEMIC PRESS INC. USA LNKD- DOI:10.1016/J.AB.2011.06.035, (20111101), vol. 418, no. 1, ISSN 0003-2697, pages 143 - 148, XP002672410 [A] 1-19 * abstract * * page 146; figure 3 *

DOI:   http://dx.doi.org/10.1016/J.AB.2011.06.035
 [A]  - W. O. GODTFREDSEN ET AL, "Antitubercular Compounds Related to p-Aminosalicylic Acid.", ACTA CHEMICA SCANDINAVICA, (19530101), vol. 7, doi:10.3891/acta.chem.scand.07-0781, ISSN 0904-213X, pages 781 - 789, XP055050836 [A] 1-19 * abstract * * page 785; table 7; compound first *

DOI:   http://dx.doi.org/10.3891/acta.chem.scand.07-0781
 [A]  - DRAIN D J ET AL, "4-Aminosalicylic Acid and its Derivatives", JOURNAL OF THE CHEMICAL SOCIETY, CHEMICAL SOCIETY, LETCHWORTH; GB, (19490101), doi:10.1039/JR9490001498, ISSN 0368-1769, pages 1498 - 1503, XP002084241 [A] 1-19 * abstract * * methyl 4-acetylsulphanilamidosalicylate; page 1502 *

DOI:   http://dx.doi.org/10.1039/jr9490001498
 [A]  - TAMAZAWA K ET AL, "Synthesis of [carbonyl-<14>C]- and (methoxy-d3)-labeled N-[(2RS, 3RS)-1-benzyl-2-methyl-3-pyrrolidinyl]-5-chloro-2-methoxy-4-(methylam ino)b enzamide (YM-09151-2) a new potent neuroleptic agent", JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS 1984 GB, (1984), vol. 21, no. 5, ISSN 0362-4803, pages 441 - 453, XP002672411 [A] 1-19 * abstract * * page 443; compounds 3a,c *

DOI:   http://dx.doi.org/10.1002/jlcr.2580210507
 [A]  - K. BENEDIKT AND H. EIBL, "Über einige Derivate der p-Aminosalicylsäure und ihre tuberkulostatische Wirksamkeit", MONATSHEFTE FÜR CHEMIE / CHEMICAL MONTHLY, (1949), vol. 81, no. 3, doi:10.1007/BF00903044, pages 419 - 423, XP002672412 [A] 1-19 * 4-Acetylsulfanylamido-salicylsäureäthylester; page 421; table 1 *

DOI:   http://dx.doi.org/10.1007/BF00903044
 [A]  - ANGULO, J.; MUNICIO, A. M., "Potential antitubercular compounds. II. Synthesis of pyridine-4-sulfonamides", ANALES DE LA REAL SOCIEDAD ESPANOLA DE FISICA Y QUIMICA, SERIE B: QUIMICA, (19590101), vol. 55B, ISSN 0034-088X, pages 527 - 532, XP008159576 [A] 1-19 * abstract * * page 530; table -; compounds p-aminosalicilato etilo *
 [A]  - WENDT B ET AL, "Toluidinesulfonamide hypoxia-induced factor 1 inhibitors: Alleviating drug-drug interactions through use of pubchem data and comparative molecular field analysis guided synthesis", JOURNAL OF MEDICINAL CHEMISTRY 20110609 AMERICAN CHEMICAL SOCIETY USA LNKD- DOI:10.1021/JM200272H, (20110609), vol. 54, no. 11, ISSN 0022-2623, pages 3982 - 3986, XP002672413 [A] 1-19 * abstract * * page 3983; table 1; compounds 1-7 *

DOI:   http://dx.doi.org/10.1021/JM200272H
by applicantWO0076984
 US6465467
 WO2008156783
 US2010267815
 WO2011103557
 US2012302631
    - WARBURG, SCIENCE, (1956), vol. 123, pages 309 - 314
    - VANDER HEIDEN ET AL., SCIENCE, (2009), vol. 324, page 1029
    - BROWN, CANCER RES., (1999), vol. 59, pages 5863 - 5870
    - WALENTA; MUELLER-KLIESER, SEMIN. RADIAT. ONCOL., (2004), vol. 14, pages 267 - 274
    - WALENTA ET AL., CURR.MED. CHEM., (2004), vol. 11, pages 2195 - 2204
    - PAN; MAK, SCI. STKE, (2007), vol. 381, page EL4
    - BACHE ET AL., CURR. MED. CHEM., (2008), vol. 15, pages 322 - 338
    - LIU ET AL., BIOCHEMISTRY, (2001), vol. 40, no. 5, pages 542 - 5547
    - LIU ET AL., BIOCHEM. PHARMACOL., (2002), vol. 64, pages 1745 - 1751
    - XU ET AL., CANCER RES., (2005), vol. 65, pages 613 - 621
    - RAMANATHAN ET AL., PROC. NATL. ACAD. SCI. USA, (2005), vol. 102, pages 5992 - 5997
    - CHESNEY ET AL., PROC.NATL. ACAD. SCI. USA, (1999), vol. 96, pages 3047 - 3052
    - TELANG ET AL., ONCOGENE, (2006), vol. 25, pages 7225 - 7234
    - ANDO ET AL., J NIPPON MED SCH, (2010), vol. 77, no. 2, pages 97 - 105
    - DEL REY ET AL., ARTHRITIS & RHEUMATISM, (2010), vol. 62, pages 3584 - 3594
    - MINCHENKO ET AL., FEBS LETT., (2004), vol. 576, pages 14 - 20
    - MINCHENKO ET AL., BIOCHEMIE, (2005), vol. 87, pages 1005 - 1010
    - BO- BARYKINA ET AL., ACTA BIOCHEMICA POLONICA, (2006), vol. 3, pages 789 - 799
    - ROS ET AL., CANCER DISCOV., (2012), vol. 2, no. 4, pages 328 - 43
    - SAKAKIBARA ET AL., J. BIO CHEM, (1984), vol. 259, pages 14023 - 14028
    - HIRATA ET AL., BIOSCI. BIOTECHNOL. BIOCHEM., (2000), vol. 64, pages 2047 - 2052
    - KIM ET AL., J. MOL. BIOL., (2007), vol. 370, pages 14 - 26
    - CHROCHET ET AL., ANAL. BIOCHEM., (2011), vol. 418, pages 143 - 148
    - SEO ET AL., PLOSONE, (2011), vol. 9, page E24179
    - CLEM ET AL., MOL. CANCER THER., (2008), vol. 7, pages 110 - 120
    - "Biotransformation of Drugs", GOODMAN; GILMAN'S, The Pharmacological basis of Therapeutics, 8th ed.,, MCGRAW-HILL, (1992), pages 13 - 15
    - PLÉ ET AL., J. HETEROCYCLIC CHEM., (1988), vol. 25, pages 1271 - 1272
    - XIE ET AL., TETRAHEDRON LETT., (2004), vol. 45, pages 6235 - 6237
    - GRAHAM ET AL., J. MED. CHEM., (1990), vol. 33, pages 749 - 754
    - PAQUETTE, Encyclopedia of Reagents for Organic Synthesis
    - JIANG ET AL., TETRAHEDRON LETT., (2006), vol. 47, pages 197 - 200
    - HARRIS ET AL., ORG. LETT, (2001), vol. 3, no. 21, pages 3417 - 3419
    - PIE ET AL., J. HETEROCYCLIC CHEM., (1988), vol. 25, pages 1271 - 1272
    - PILKIS ET AL., ANNU. REV. BIOCHEM., (1995), vol. 64, pages 799 - 835
    - OKAR ET AL., TRENDS BIOCHEM. SCI., (2001), vol. 26, pages 30 - 5
    - RIDER ET AL., BIOCHEM J., (2007), vol. 381, pages 561 - 579
    - VAN SCHAFTINGEN ET AL., EUR. J. BIOCHEM., (1982), vol. 129, pages 191 - 5
    - VAN SCHAFTINGEN, Methods of Enzymatic Analysis, 3rd edn.,, VERLAG CHEMIE, (1984), vol. 6, pages 335 - 341
    - BRUNI ET AL., ANAL. BIOCHEM., (1989), vol. 178, pages 324 - 6
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.